Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the...
Sábháilte in:
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | LEABHAR |
| Foilsithe / Cruthaithe: |
Elsevier,
2017-06-01T00:00:00Z.
|
| Ábhair: | |
| Rochtain ar líne: | Connect to this object online. |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
| Gairmuimhir: |
A1234.567 |
|---|---|
| Cóip 1 | Ar fáil |